Apr 9, 2025 8:00 am EDT Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
Feb 25, 2025 8:00 am EST Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Feb 13, 2025 8:00 am EST Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Feb 10, 2025 8:05 am EST Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Feb 10, 2025 8:01 am EST Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Dec 4, 2024 8:00 am EST Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference
Nov 13, 2024 8:00 am EST Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update
Oct 30, 2024 8:00 am EDT Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024